Page 4 - Jeannie Neufeld News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
- Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)
- The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials(1)
- Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence(2,3)
News provided by
Share this article
Share this article
EAST HANOVER, N.J., June 1, 2021 /PRNewswire/  Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx ....

United States , San Antonio , University Of Texas , John Browning , Dermatol Venerol , Julie Masow , Michael Meo , Sloan Simpson , Victor Bulto , Jeannie Neufeld , University Of Texas Health , Drug Administration , Exchange Commission , Novartis Europharm , American Academy Of Dermatology , Nj Novartis Pharmaceuticals Corporation , Novartis Pharmaceuticals Corporation , National Psoriasis Foundation , Novartis Pharmaceuticals Corp , Adjunct Associate Professor , Texas Health , Novartis Pharmaceuticals , Medication Guide , East Hanover , Pharmaceuticals Corporation , American Academy ,